NMD Pharma A/S: Financial statements 2021
CVR: 36899069
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
NMD Pharma A/S (CVR 36899069) has filed annual accounts for 2021. In 2021, the company reported a gross profit of EUR -11,029,051 and a net result of EUR -13,614,082 compared with EUR -9,928,027 the year before. Equity in the 2021 report amounted to EUR 2,595,580. The solvency ratio was 52.8%. The company had 26 employees in the financial year.
- Gross Profit
- EUR -11,029,051
- Profit/Loss
- EUR -13,614,082
- Equity
- EUR 2,595,580
- Total Assets
- EUR 4,919,746
- Employees
- 26
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -11 mio. EUR | -13.6 mio. EUR | 2.6 mio. EUR | 26 |
| 2020 | - | -7.9 mio. EUR | -9.9 mio. EUR | 9.2 mio. EUR | 22 |
| 2019 | - | -7.1 mio. EUR | -8.5 mio. EUR | 140 t. EUR | 17 |
| 2018 | - | -4.7 mio. EUR | -5.5 mio. EUR | 88 t. EUR | 14 |
| 2017 | - | -17.9 mio. | -21.9 mio. | -8.7 mio. | 13 |
Official annual report
Find more companies like NMD Pharma A/S
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
NMD Pharma A/S has published its annual report for 2020. Gross profit came to DKK -7,870,124, and the net result was DKK -9,928,027.
About NMD Pharma A/S
NMD Pharma A/S is a Danish company of the type Aktieselskab based in Aarhus N, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named NMD Pharma ApS. The management consists of Thomas Holm Pedersen. The board consists of Michael Thomas Heffernan (chair), Anja Ulrike Harmeier, Christian Ellebæk Elling and Ivan Andreevich Burkov. The company's owners include LUNDBECKFOND INVEST A/S, Novo Holdings A/S and Roche Finance Ltd.. The company has 64 employees (2026). In 2025, the company reported a gross profit of EUR -26,063,175 and a net result of EUR -32,985,370 compared with EUR -32,253,700 the year before. Equity in the 2025 report amounted to EUR 12,410,475.